torvalipin 20 mg filmsko obložene tablete
actavis group hf - atorvastatin - filmsko obložena tableta - atorvastatin 20 mg / 1 tableta - atorvastatin
torvalipin 40 mg filmsko obložene tablete
actavis group hf - atorvastatin - filmsko obložena tableta - atorvastatin 40 mg / 1 tableta - atorvastatin
torvalipin 10 mg filmsko obložene tablete
actavis group hf - atorvastatin - filmsko obložena tableta - atorvastatin 10 mg / 1 tableta - atorvastatin
torvalipin 20 mg filmsko obložene tablete
actavis group hf - atorvastatin - filmsko obložena tableta - atorvastatin 20 mg / 1 tableta - atorvastatin
torvalipin 40 mg filmsko obložene tablete
actavis group hf - atorvastatin - filmsko obložena tableta - atorvastatin 40 mg / 1 tableta - atorvastatin
torvalipin 80 mg filmsko obložene tablete
actavis group hf - atorvastatin - filmsko obložena tableta - atorvastatin 80 mg / 1 tableta - atorvastatin
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.
beriplast p combi-set 1 ml prašek in vehikel za lepilo za tkiva
csl behring gmbh - aprotinin; fibrinogen, humani; koagulacijski faktor xiii, humani - prašek in vehikel za lepilo za tkiva - aprotinin 1000 mg / 1 ml fibrinogen, humani90 mg / 1 ml koagulacijski faktor xiii, humani60 mg / 1 ml; fibrinogen, humani 90 mg / 1 ml koagulacijski faktor xiii, humani60 mg / 1 ml; koagulacijski faktor xiii, humani 60 mg / 1 ml - kombinacije
beriplast p combi-set 3 ml prašek in vehikel za lepilo za tkiva
csl behring gmbh - aprotinin; fibrinogen, humani; koagulacijski faktor xiii, humani - prašek in vehikel za lepilo za tkiva - aprotinin 3000 mg / 1 ml fibrinogen, humani270 mg / 1 ml koagulacijski faktor xiii, humani180 mg / 1 ml; fibrinogen, humani 270 mg / 1 ml koagulacijski faktor xiii, humani180 mg / 1 ml; koagulacijski faktor xiii, humani 180 mg / 1 ml - kombinacije
torisel
pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastična sredstva - ledvične celice carcinomatorisel je določen za prvo linijo za zdravljenje odraslih bolnikov z napredovalim ledvičnim-cell carcinoma (rkc), ki so najmanj tri od šestih prognostic dejavniki tveganja. plašč-celice lymphomatorisel je indiciran za zdravljenje odraslih bolnikov z relapsed in / ali ognjevzdržni plašč-celični limfom (mcl).